| Target General Infomation |
| Target ID |
T06037
|
| Former ID |
TTDR01391
|
| Target Name |
mRNA of human Jun-N-terminal kinase-2 (JNK2)
|
| Gene Name |
MAPK9
|
| Synonyms |
JNK55 (mRNA); MAP kinase 9(mRNA); MAPK 9 (mRNA); Mitogenactivated protein kinase 9 (mRNA); SAPK1a (mRNA); Stressactivated protein kinase 1a (mRNA); Stressactivated protein kinase JNK2 (mRNA); cJun Nterminal kinase 2 (mRNA); MAPK9
|
| Target Type |
Research
|
| Disease |
Cancer [ICD9: 140-229; ICD10: C00-C96] |
|---|
| BioChemical Class |
Kinase
|
| Target Validation |
T06037
|
| UniProt ID |
|
| EC Number |
EC 2.7.11.24
|
| Sequence |
MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRP
FQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIH
MELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNF
MMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQ
LGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSK
MLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEV
MDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPL
EGCR
|
| Inhibitor |
AC1LG8KT |
Drug Info |
[1] |
|---|
| aminopyridine deriv. 2 |
Drug Info |
[2] |
| AS-601245 |
Drug Info |
[3] |
| IN-1166 |
Drug Info |
[4] |
| JNK-IN-8 |
Drug Info |
[5] |
| N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide |
Drug Info |
[2] |
| N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide |
Drug Info |
[2] |
| N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide |
Drug Info |
[2] |
| Pathways |
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
cAMP signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Protein processing in endoplasmic reticulum
|
|
Wnt signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
T cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Dopaminergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Insulin signaling pathway
|
|
GnRH signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Prolactin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Influenza A
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Pancreatic cancer
|
|
Choline metabolism in cancer
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Apoptosis signaling pathway
|
|
B cell activation
|
|
FAS signaling pathway
|
|
Huntington disease
|
|
Integrin signalling pathway
|
|
Interferon-gamma signaling pathway
|
|
Oxidative stress response
|
|
Parkinson disease
|
|
TGF-beta signaling pathway
|
|
T cell activation
|
|
Toll receptor signaling pathway
|
|
Ras Pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Noncanonical Wnt signaling pathway
|
|
CD40/CD40L signaling
|
|
CDC42 signaling events
|
|
FAS (CD95) signaling pathway
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
Glucocorticoid receptor regulatory network
|
|
IL2-mediated signaling events
|
|
Rapid glucocorticoid signaling
|
|
FoxO family signaling
|
|
p75(NTR)-mediated signaling
|
|
ErbB1 downstream signaling
|
|
ATF-2 transcription factor network
|
|
ErbB2/ErbB3 signaling events
|
|
PDGFR-beta signaling pathway
|
|
Nephrin/Neph1 signaling in the kidney podocyte
|
|
p53 pathway
|
|
Downstream signaling in na&
|
|
#xef
|
|
ve CD8+ T cells
|
|
RAC1 signaling pathway
|
|
Regulation of retinoblastoma protein
|
|
Signaling events mediated by focal adhesion kinase
|
|
Glypican 3 network
|
|
IL12 signaling mediated by STAT4
|
|
Reactome
|
Oxidative Stress Induced Senescence
|
|
FCERI mediated MAPK activation
|
|
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
|
|
Activation of the AP-1 family of transcription factors
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
DNA Damage Response (only ATM dependent)
|
|
TCR Signaling Pathway
|
|
TGF Beta Signaling Pathway
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
TGF beta Signaling Pathway
|
|
Wnt Signaling Pathway Netpath
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
JAK/STAT
|
|
ATM Signaling Pathway
|
|
BDNF signaling pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Corticotropin-releasing hormone
|
|
AGE/RAGE pathway
|
|
TNF alpha Signaling Pathway
|
|
B Cell Receptor Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
RANKL/RANK Signaling Pathway
|
|
IL-1 signaling pathway
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301. Epub 2006 Dec 15. |
|---|
| REF 2 | J Med Chem. 2006 Jun 15;49(12):3563-80.Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. |
|---|
| REF 3 | Biochem J. 2007 Dec 15;408(3):297-315.The selectivity of protein kinase inhibitors: a further update. |
|---|
| REF 4 | J Med Chem. 2007 Jun 28;50(13):3143-7. Epub 2007 Jun 7.Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. |
|---|
| REF 5 | Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54. |
|---|
